Yuan J. Pétermann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuan J. Pétermann has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bibie Said
Department of Health and Biomedical Sciences, School of Life Sciences, Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha 23100, Tanzania
2 shared publications - Monia Guidi
Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland
2 shared publications - Stellah George Mpagama
Medical, Kibong’oto Infectious Diseases Hospital, Kilimanjaro, Tanzania, United Republic of
2 shared publications - Yann Thoma
School of Engineering and Management Vaud, HES-SO University of Applied Sciences and Arts Western Switzerland, 1401 Yverdon-les-Bains, Switzerland
2 shared publications - Annie E. Cathignol
HEIG-VD
1 shared publication - Chantal Csajka
Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne , Lausanne
1 shared publication
Latest Publications
- Open Access
- 4 November 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (11) , 316
Rifampicin Pharmacokinetics and Clinical Outcomes in Tuberculosis Patients with Comorbidities: A Descriptive Longitudinal Analysis
Tuberculosis (TB) patients with comorbidities may have altered rifampicin pharmacokinetics (PK), particularly in sub-Saharan Africa. This can affect treatment response and suggests a role for therapeutic drug monitoring (TDM) in identifying suboptimal exposure. We describe the rifampicin PK in Tanzanian TB patients with HIV, diabetes mellitus (DM), or malnutrition. Participants were enrolled and followed for six months, with PK sampling at baseline and at week 2. All received standard rifampicin, isoniazid, pyrazinamide, and ethambutol. Plasma concentrations were measured via high-performance liquid chromatography (HPLC) before dosing and at 2 ± 1, 5 ± 1, and 12 ± 3 h post-dose. The area under the concentration–time curve to the last measured concentration (AUC0-last) and the peak plasma concentration (Cmax) were derived by non-compartmental analysis. Treatment outcomes were assessed at 6 months using WHO definitions. Of 40 participants (median age 45 years), 34 had a valid PK sample at both visits. Exposure declined between visits in most participants, but magnitude and direction change differed by comorbidity group. The largest median decline occurred in combined HIV–malnutrition (−23.7% for Cmax, and −29.8% AUC0-last), whereas the malnutrition-only group showed no consistent direction, and some of its participants had higher exposure at week 2. In the adjusted mixed-effects model, visit was the only variable whose confidence interval excluded zero (AUC0-last −22.6%, 95% CI, −28.5%, to −16.2%; Cmax −20.1%, 95% CI, −25.5%, −14.3%); HIV, malnutrition, their interaction, age, sex, and mid-upper arm circumference (MUAC) showed no clear association with exposure. Six-month outcomes differed by comorbidity, with deaths concentrated among HIV-positive participants, particularly those who were also malnourished. These findings support combining TDM with individualized dosing, including model-informed precision dosing delivered through clinical decision support systems to optimize rifampicin exposure in high-risk groups.
- 4 November 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (11) , 316
Open AccessRifampicin Pharmacokinetics and Clinical Outcomes in Tuberculosis Patients with Comorbidities: A Descriptive Longitudinal Analysis
Tuberculosis (TB) patients with comorbidities may have altered rifampicin pharmacokinetics (PK), particularly in sub-Saharan Africa. This can affect treatment response and suggests a role for therapeutic drug monitoring (TDM) in identifying suboptimal exposure. We describe the rifampicin PK in Tanzanian TB patients with HIV, diabetes mellitus (DM), or malnutrition. Participants were enrolled and followed for six months, with PK sampling at baseline and at week 2. All received standard rifampicin, isoniazid, pyrazinamide, and ethambutol. Plasma concentrations were measured via high-performance liquid chromatography (HPLC) before dosing and at 2 ± 1, 5 ± 1, and 12 ± 3 h post-dose. The area under the concentration–time curve to the last measured concentration (AUC0-last) and the peak plasma concentration (Cmax) were derived by non-compartmental analysis. Treatment outcomes were assessed at 6 months using WHO definitions. Of 40 participants (median age 45 years), 34 had a valid PK sample at both visits. Exposure declined between visits in most participants, but magnitude and direction change differed by comorbidity group. The largest median decline occurred in combined HIV–malnutrition (−23.7% for Cmax, and −29.8% AUC0-last), whereas the malnutrition-only group showed no consistent direction, and some of its participants had higher exposure at week 2. In the adjusted mixed-effects model, visit was the only variable whose confidence interval excluded zero (AUC0-last −22.6%, 95% CI, −28.5%, to −16.2%; Cmax −20.1%, 95% CI, −25.5%, −14.3%); HIV, malnutrition, their interaction, age, sex, and mid-upper arm circumference (MUAC) showed no clear association with exposure. Six-month outcomes differed by comorbidity, with deaths concentrated among HIV-positive participants, particularly those who were also malnourished. These findings support combining TDM with individualized dosing, including model-informed precision dosing delivered through clinical decision support systems to optimize rifampicin exposure in high-risk groups.
- Open Access
The TuberXpert project protocol: Towards a Clinical Decision Support System for therapeutic anti-tuberculosis medical drugs monitoring in Tanzania
Introduction: The End Tuberculosis (TB) Strategy requires a novel patient treatment approach contrary to the “one-size fits all” model. It is well known that each patient’s physiology is different and leads to various rates of drug elimination. Therapeutic Drug Monitoring (TDM) offers a way to manage drug dosage adaptation but requires trained pharmacologists, which is scarce in resource-limited settings. We, therefore, aim to create an unprecedented Clinical Decision Support System (CDSS) that will offer a printable report containing advice for the field clinicians to guide the adaptation of TB treatment depending on the patient. Methods and analysis: A population pharmacokinetic model for rifampicin will be developed and thoroughly validated, before being implemented into Tucuxi, an existing Model Informed Precision Dosing software. A cross-sectional study will be conducted to define the best way to display information to clinicians. In addition, a pragmatic prospective study will focus on a decision tree that will be implemented as a CDSS. Expert pharmacologists will validate the CDSS, and, finally, field implementation in Tanzania will occur coupled with a prospective study to assess clinicians’ adherence to the CDSS recommendations. Ethics and dissemination: This is a game-changing transdisciplinary project combining technology and pharmacometrics to enable appropriate dosages of anti-TB drugs in TB patients at various levels of the healthcare delivery system in TB-endemic settings. The project is part of the Adaptive Diseases control Expert Programme in Tanzania, which has been approved at the local health research committee serving Kibong’oto Infectious Diseases Hospital (KIDH) and National Health Research Committee with reference numbers KNCHREC003 and NIMR/HQ/R.8a/Vol.IX/2988, respectively. Furthermore, the Ministries of Health and Regional Administrative & Local Government Authority have endorsed the implementation of this protocol. Dissemination will be done through scientific publications, conferences, and local press in Tanzania. Social media will also be used to gain more visibility. Strengths and limitations of this study: - To our knowledge, this is the first study to investigate the application of CDSS technology at varying healthcare delivery systems levels to guide TDM in TB patients in TB-endemic settings. - Routine implementation of TDM-CDSS, particularly for rifampicin, a backbone for TB treatment, is expected to transform TB’s clinical management in resource-limited settings. - Anti-TB dosage optimization will improve treatment outcomes of patients who would otherwise succumb or develop drug-resistant TB because of sub-optimal drug exposure. This will considerably contribute to the End TB strategy, particularly with arduous forms of TB with either Human Immunodeficiency Virus (HIV) co-infection or coexistent Diabetes Mellitus (DM) or malnutrition. - Clinicians could also use the CDSS decision tree without access to IT infrastructure. - A lack of computer infrastructure in health facilities may prevent implementing a centralized system in resource-limited countries.
Open AccessThe TuberXpert project protocol: Towards a Clinical Decision Support System for therapeutic anti-tuberculosis medical drugs monitoring in Tanzania
Introduction: The End Tuberculosis (TB) Strategy requires a novel patient treatment approach contrary to the “one-size fits all” model. It is well known that each patient’s physiology is different and leads to various rates of drug elimination. Therapeutic Drug Monitoring (TDM) offers a way to manage drug dosage adaptation but requires trained pharmacologists, which is scarce in resource-limited settings. We, therefore, aim to create an unprecedented Clinical Decision Support System (CDSS) that will offer a printable report containing advice for the field clinicians to guide the adaptation of TB treatment depending on the patient. Methods and analysis: A population pharmacokinetic model for rifampicin will be developed and thoroughly validated, before being implemented into Tucuxi, an existing Model Informed Precision Dosing software. A cross-sectional study will be conducted to define the best way to display information to clinicians. In addition, a pragmatic prospective study will focus on a decision tree that will be implemented as a CDSS. Expert pharmacologists will validate the CDSS, and, finally, field implementation in Tanzania will occur coupled with a prospective study to assess clinicians’ adherence to the CDSS recommendations. Ethics and dissemination: This is a game-changing transdisciplinary project combining technology and pharmacometrics to enable appropriate dosages of anti-TB drugs in TB patients at various levels of the healthcare delivery system in TB-endemic settings. The project is part of the Adaptive Diseases control Expert Programme in Tanzania, which has been approved at the local health research committee serving Kibong’oto Infectious Diseases Hospital (KIDH) and National Health Research Committee with reference numbers KNCHREC003 and NIMR/HQ/R.8a/Vol.IX/2988, respectively. Furthermore, the Ministries of Health and Regional Administrative & Local Government Authority have endorsed the implementation of this protocol. Dissemination will be done through scientific publications, conferences, and local press in Tanzania. Social media will also be used to gain more visibility. Strengths and limitations of this study: - To our knowledge, this is the first study to investigate the application of CDSS technology at varying healthcare delivery systems levels to guide TDM in TB patients in TB-endemic settings. - Routine implementation of TDM-CDSS, particularly for rifampicin, a backbone for TB treatment, is expected to transform TB’s clinical management in resource-limited settings. - Anti-TB dosage optimization will improve treatment outcomes of patients who would otherwise succumb or develop drug-resistant TB because of sub-optimal drug exposure. This will considerably contribute to the End TB strategy, particularly with arduous forms of TB with either Human Immunodeficiency Virus (HIV) co-infection or coexistent Diabetes Mellitus (DM) or malnutrition. - Clinicians could also use the CDSS decision tree without access to IT infrastructure. - A lack of computer infrastructure in health facilities may prevent implementing a centralized system in resource-limited countries.